Advertisement

Topics

Tarveda Therapeutics to Present Data from Phase 1 Study of PEN-221 at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

08:00 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that it will present Phase 1 results ...

Other Sources for this Article

MacDougall Biomedical Communications
George E. MacDougall, 781-235-3060
george@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Tarveda Therapeutics to Present Data from Phase 1 Study of PEN-221 at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...